Australia markets open in 8 hours 41 minutes

Arch Biopartners Inc. (ACHFF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
2.2400-0.0050 (-0.22%)
As of 9:44AM EDT. Market open.
Full screen
Trade prices are not sourced from all markets
Previous close2.2450
Open2.2325
Bid0.0000 x 0
Ask0.0000 x 0
Day's range2.2325 - 2.2400
52-week range0.9100 - 2.4190
Volume1,600
Avg. volume25,706
Market cap142.356M
Beta (5Y monthly)1.04
PE ratio (TTM)N/A
EPS (TTM)-0.0450
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Unaware of Any Undisclosed Material Change

    TORONTO, Oct. 15, 2021 (GLOBE NEWSWIRE) -- At the request of the Investment Industry Regulatory Organization of Canada (IIROC), Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF) wishes to confirm that the Company’s management is unaware of any undisclosed material change in the Company’s operations that would account for the recent increase in market activity. About Arch Biopartners Arch Biopartners Inc. is a clinical stage company focused on the development of

  • GlobeNewswire

    Arch Biopartners Provides Update on Phase II Trial for LSALT Peptide

    TORONTO, Aug. 05, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, today provided an update that the analysis of the results of the Phase II trial of its lead drug LSALT peptide (Metablok) is ongoing and will be disclosed to the public following third-party, scientific peer review. After the recruitment of the last patient into th

  • GlobeNewswire

    Arch Scientists Awarded CIHR Grant to Study LSALT for the Prevention of Chronic Disease

    TORONTO, July 14, 2021 (GLOBE NEWSWIRE) -- Arch Biopartners Inc. (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), a clinical stage company developing new drug candidates for treating organ damage caused by inflammation, announced today that Arch scientists have been awarded a Canadian Institutes of Health Research (CIHR) Team Grant worth $750,000 to study the potential benefit for the LSALT peptide (Metablok) to prevent inflammation in chronic kidney and lung diseases. The CIHR gr